ArticleDrug design, development and therapy2021

Consolidation Treatment and Long-Term Prognosis of Rituximab in Minimal Change Disease and Focal Segmental Glomerular Sclerosis.

Li Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.